JANET B. ARROWSMITH, M.D.; JULIE B. MILSTIEN, Ph.D.; JOEL N. KURITSKY, M.D.; GENESIO MURANO, Ph.D.
To the editor: Evaluation of the reported association between streptokinase therapy and the Guillain-Barré syndrome (1, 2) brings to light problems encountered by the Food and Drug Administration (FDA) in investigating serious, unexpected drug- or biologic-product-related events. Guillain-Barré syndrome has been reported to occur after viral and bacterial illnesses, immunization with swine influenza and other vaccines, surgical procedures, psychological disorders, and pregnancy (3). The syndrome is presumed to be the result of an abnormal immunologic process. Streptokinase, a bacterial protein, elicits a host immune response, and so, development of the syndrome after exposure to streptokinase may be biologically plausible.
ARROWSMITH JB, MILSTIEN JB, KURITSKY JN, MURANO G. Streptokinase and the Guillain-Barré Syndrome. Ann Intern Med. ;103:302. doi: 10.7326/0003-4819-103-2-302_2
Download citation file:
Published: Ann Intern Med. 1985;103(2):302.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use